CLINUVEL product studied for Sun exposure DNA repair
Biopharmaceurical company CLINUVEL has announced results from a study evaluating the DNA-repair capacity of its afamelanotide product on skin of healthy volunteers exposed to ultraviolet (UV) radiation. The study, conducted at Salford Royal Hospital, Manchester suggests that afamelanotide leads to reduction of differentially expressed genes (DEGs) in exposed skin, according to an ASX announcement. The…